New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:04 EDTLGNDLigand says LGD-6972 well-tolerated in Phase 1 study
Ligand Pharmaceuticals announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligandís novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Associationís 74th Scientific Sessions meeting underway in San Francisco. Highlights of the single-ascending dose trial involving a total of 56 subjects include: LGD-6972 was well-tolerated; there were no clinically significant or dose-dependent changes in hematology, clinical chemistry, urinalysis, ECG or vital signs, and no serious adverse events. LGD-6972 was well-absorbed after oral administration; peak plasma concentrations were reached approximately 5 to 8 hours post dose with a long elimination half-life of approximately 50 hours, supporting once-daily dosing. After a single dose, LGD-6972 reduced fasting plasma glucose in normal healthy volunteers and in subjects with type 2 diabetes. Fasting plasma glucose was reduced by 57 mg/dL in subjects with type 2 diabetes, suggesting a robust response in this acute study.
News For LGND From The Last 14 Days
Check below for free stories on LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2014
08:03 EDTLGNDGlaxoSmithKline receives FDA approval for sNDA for Promacta/Revolade
Ligand Pharmaceuticals Incorporated (LGND) announced that its partner GlaxoSmithKline (GSK) has received approval of a supplemental New Drug Application for the once-daily use of Promacta/Revolade in patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. SAA is a blood disorder where the bone marrow fails to make enough red blood cells, white blood cells and platelets.2 Eltrombopag, an oral thrombopoietin receptor agonist, works by helping to induce proliferation and differentiation of bone marrow stem cells to increase production of blood cells.
August 25, 2014
11:45 EDTLGNDLemelson says Ligand has 'lost favor with largest investors'
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use